دورية أكاديمية
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
| العنوان: | Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer. |
|---|---|
| المؤلفون: | Tan AC; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Lai GGY; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Saw SPL; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Chua KLM; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore., Takano A; Division of Pathology, Singapore General Hospital, Singapore, Singapore., Ong BH; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.; Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore., Koh TPT; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Jain A; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Tan WL; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Ng QS; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Rajasekaran T; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Kalashnikova E; Natera, Inc, San Carlos, California, USA., Renner D; Natera, Inc, San Carlos, California, USA., Sudhaman S; Natera, Inc, San Carlos, California, USA., Malhotra M; Natera, Inc, San Carlos, California, USA., Sethi H; Natera, Inc, San Carlos, California, USA., Liu MC; Natera, Inc, San Carlos, California, USA., Aleshin A; Natera, Inc, San Carlos, California, USA., Lim WT; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.; Institute of Molecular and Cell Biology, Singapore, Singapore., Tan EH; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Skanderup AJ; Genome Institute of Singapore, Singapore, Singapore., Ang MK; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore., Tan DSW; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Duke-NUS Medical School, National University of Singapore, Singapore, Singapore.; Genome Institute of Singapore, Singapore, Singapore. |
| المصدر: | Cancer [Cancer] 2024 May 15; Vol. 130 (10), pp. 1758-1765. Date of Electronic Publication: 2024 Feb 29. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005- >: Hoboken, NJ : Wiley Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.] |
| مواضيع طبية MeSH: | Lung Neoplasms*/genetics , Lung Neoplasms*/blood , Lung Neoplasms*/pathology , Circulating Tumor DNA*/blood , Circulating Tumor DNA*/genetics , Neoplasm Recurrence, Local*/genetics , Neoplasm Recurrence, Local*/diagnosis , Carcinoma, Non-Small-Cell Lung*/genetics , Carcinoma, Non-Small-Cell Lung*/blood , Carcinoma, Non-Small-Cell Lung*/pathology , High-Throughput Nucleotide Sequencing*/methods , Neoplasm, Residual*/genetics , Neoplasm, Residual*/diagnosis , Neoplasm Staging*, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Early Detection of Cancer/methods ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/blood ; Adult ; Aged, 80 and over ; Multiplex Polymerase Chain Reaction/methods |
| مستخلص: | Background: In early-stage non-small cell lung cancer (NSCLC), recurrence is frequently observed. Circulating tumor DNA (ctDNA) has emerged as a noninvasive tool to risk stratify patients for recurrence after curative intent therapy. This study aimed to risk stratify patients with early-stage NSCLC via a personalized, tumor-informed multiplex polymerase chain reaction (mPCR) next-generation sequencing assay. Methods: This retrospective cohort study included patients with stage I-III NSCLC. Recruited patients received standard-of-care management (surgical resection with or without adjuvant chemotherapy, followed by surveillance). Whole-exome sequencing of NSCLC resected tissue and matched germline DNA was used to design patient-specific mPCR assays (Signatera, Natera, Inc) to track up to 16 single-nucleotide variants in plasma samples. Results: The overall cohort with analyzed plasma samples consisted of 57 patients. Stage distribution was 68% for stage I and 16% each for stages II and III. Presurgery (i.e., at baseline), ctDNA was detected in 15 of 57 patients (26%). ctDNA detection presurgery was significantly associated with shorter recurrence-free survival (RFS; hazard ratio [HR], 3.54; 95% confidence interval [CI], 1.00-12.62; p = .009). In the postsurgery setting, ctDNA was detected in seven patients, of whom 100% experienced radiological recurrence. ctDNA positivity preceded radiological findings by a median lead time of 2.8 months (range, 0-12.9 months). Longitudinally, ctDNA detection at any time point was associated with shorter RFS (HR, 16.1; 95% CI, 1.63-158.9; p < .0001). Conclusions: ctDNA detection before surgical resection was strongly associated with a high risk of relapse in early-stage NSCLC in a large unique Asian cohort. Prospective studies are needed to assess the clinical utility of ctDNA status in this setting. (© 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.) |
| References: | Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019;11:943‐953. doi:10.2147/cmar.s187317. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7‐30. doi:10.3322/caac.21590. Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I–III non‐metastatic non‐small‐cell lung cancer. Nat Rev Clin Oncol. 2021;18(9):547‐557. doi:10.1038/s41571‐021‐00501‐4. Saw SPL, Ong B‐H, Chua KLM, Takano A, Tan DSW. Revisiting neoadjuvant therapy in non‐small‐cell lung cancer. Lancet Oncol. 2021;22(11):e501‐e516. doi:10.1016/s1470‐2045(21)00383‐1. Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39‐51. doi:10.1016/j.jtho.2015.09.009. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non‐small‐cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2017;28(suppl 4):IV1‐IV21. doi:10.1093/annonc/mdx222. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342‐2350. doi:10.1056/nejmoa1809697. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non‐small‐cell lung cancer (IMpower010): a randomised, multicentre, open‐label, phase 3 trial. Lancet. 2021;398(10308):1344‐1357. doi:10.1016/s0140‐6736(21)02098‐5. O’Brien M, Paz‐Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non‐small‐cell lung cancer (PEARLS/KEYNOTE‐091): an interim analysis of a randomised, triple‐blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274‐1286. doi:10.1016/s1470‐2045(22)00518‐6. Solomon BJ, Ahn JS, Dziadziuszko R, et al. LBA2 ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early‐stage ALK+ non‐small cell lung cancer (NSCLC). Ann Oncol. 2023;34:S1295‐S1296. doi:10.1016/j.annonc.2023.10.051. Wu Y‐L, Tsuboi M, He J, et al. Osimertinib in resected EGFR‐mutated non‐small‐cell lung cancer. N Engl J Med. 2020;383(18):1711‐1723. doi:10.1056/nejmoa2027071. Frisone D, Friedlaender A, Addeo A. The role and impact of minimal residual disease in NSCLC. Curr Oncol Rep. 2021;23(12):136. doi:10.1007/s11912‐021‐01131‐w. Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC—challenges to implementing ctDNA‐based screening and MRD detection. Nat Rev Clin Oncol. 2018;15(9):577‐586. doi:10.1038/s41571‐018‐0058‐3. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early‐stage lung cancer evolution. Nature. 2017;545(7655):446‐451. doi:10.1038/nature22364. Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394‐1403. doi:10.1158/2159‐8290.cd‐17‐0716. Gale D, Heider K, Ruiz‐Valdepenas A, et al. Residual ctDNA after treatment predicts early relapse in patients with early‐stage non‐small cell lung cancer. Ann Oncol. 2022;33(5):500‐510. doi:10.1016/j.annonc.2022.02.007. Tan AC, Saw SP, Lai GG, et al. Abstract 5114: Ultra‐sensitive detection of minimal residual disease (MRD) through whole genome sequencing (WGS) using an AI‐based error suppression model in resected early‐stage non‐small cell lung cancer (NSCLC). Cancer Res. 2022;82(suppl 12):5114. doi:10.1158/1538‐7445.am2022‐5114. Zhou C, Das Thakur M, Srivastava MK, et al. 2O IMpower010: biomarkers of disease‐free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB–IIIA NSCLC. Ann Oncol. 2021;32(suppl 7):S1374. doi:10.1016/j.annonc.2021.10.018. Li N, Wang B‐X, Li J, et al. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non‐small cell lung cancer. Cancer. 2022;128(4):708‐718. doi:10.1002/cncr.33985. Zhang J‐T, Liu S‐Y, Gao W, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non‐small cell lung cancer. Cancer Discov. 2022;12(7):1690‐1701. doi:10.1158/2159‐8290.cd‐21‐1486. Chen J, Yang H, Teo ASM, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020;52(2):177‐186. doi:10.1038/s41588‐019‐0569‐6. Razavi P, Li BT, Brown DN, et al. High‐intensity sequencing reveals the sources of plasma circulating cell‐free DNA variants. Nat Med. 2019;25(12):1928‐1937. doi:10.1038/s41591‐019‐0652‐7. Chabon JJ, Hamilton EG, Kurtz DM, et al. Integrating genomic features for non‐invasive early lung cancer detection. Nature. 2020;580(7802):245‐251. doi:10.1038/s41586‐020‐2140‐0. Nakamura M, Kageyama S‐I, Hirata H, et al. Detection of pretreatment circulating tumor DNA predicts recurrence after high‐dose proton beam therapy for early‐stage non‐small cell lung cancer. Int J Radiat Oncol Biol Phys. 2023;116(5):1085‐1090. doi:10.1016/j.ijrobp.2023.02.021. Kasi PM, Fehringer G, Taniguchi H, et al. Impact of circulating tumor DNA‐based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors. JCO Precis Oncol. 2022;6:e2100181. doi:10.1200/po.21.00181. Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell‐free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124‐1131. doi:10.1001/jamaoncol.2019.0528. Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non‐small‐cell lung cancer treated with curative intent. J Clin Oncol. 2022;40(6):567‐575. doi:10.1200/jco.21.01929. |
| معلومات مُعتمدة: | International Association for the Study of Lung Cancer; NMRC/TCR/007-NCC/2013 National Medical Research Council, Singapore; NMRC/OFLCG/002-2018 National Medical Research Council, Singapore |
| فهرسة مساهمة: | Keywords: circulating tumor DNA; early‐stage lung cancer; liquid biopsy; non–small cell lung cancer |
| المشرفين على المادة: | 0 (Circulating Tumor DNA) 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20240229 Date Completed: 20240429 Latest Revision: 20240429 |
| رمز التحديث: | 20240501 |
| DOI: | 10.1002/cncr.35263 |
| PMID: | 38422026 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.35263 |